CRL
Hikma Pharmaceuticals USA, Inc.Hikma Pharmaceuticals USA, Inc. – FDA CRL
Record Details
Hikma Pharmaceuticals USA, Inc. received a Complete Response Letter from the FDA for its New Drug Application (NDA 218258) for phenobarbital sodium injection, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act. The FDA identified several key deficiencies preventing approval. Clinically, the application lacked analyzable efficacy and safety datasets, particularly from the
- Product type
- NDA (New Drug Application)
- Person
View Company Profile
ID · 81aa8665-2173-4b06-b9bc-9106fb4e67ac
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.